Rhythm Pharmaceuticals, Inc. (BMV:RYTM)

Market Cap	127.01B
Revenue (ttm)	3.20B
Net Income (ttm)	-3.63B
Shares Out	n/a
EPS (ttm)	-56.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	599
Average Volume	3,380
Open	1,866.76
Previous Close	2,025.00
Day's Range	1,866.76 - 1,866.76
52-Week Range	1,800.00 - 2,025.00
Beta	n/a
RSI	78.94
Earnings Date	Feb 24, 2026

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 283
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: RYTM

Financial Performance

In 2024, Rhythm Pharmaceuticals's revenue was $130.13 million, an increase of 68.06% compared to the previous year's $77.43 million. Losses were -$264.57 million, 43.3% more than in 2023.

Financial numbers in USD